Background Ipilimumab is an antagonistic monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) that enhances antitumor immunity by inhibiting immunosuppressive activity of regulatory T cells (Treg). the addition of ipilimumab on the initiation of lifestyle significantly improved T cell proliferation (p?=?0.0029). ATC harvested in the current presence of ipilimumab demonstrated significantly elevated mean tumor-specific cytotoxicity at… Continue reading Background Ipilimumab is an antagonistic monoclonal antibody against cytotoxic T-lymphocyte antigen-4